Canadian Miner Enforces Shareholder Agreement in China: Case Background

Canadian Miner Enforces Shareholder Agreement in China: Case Background

When a TSX-listed Canadian mining company entered into a RMB 320 million joint venture with a Chinese state-owned enterprise (SOE) to develop a rare earth processing facility in Jiangxi Province in 2018, the shareholder agreement was drafted to balance the Canadian company’s operational expertise with the SOE’s regulatory access and financing capacity. By 2022, a dispute over dividend distribution, board representation, and pre-emptive rights threatened to unravel the partnership. The Canadian minority shareholder — holding 40% of the JV’s equity — found itself facing a coordinated effort by the majority Chinese shareholder to dilute its stake and exclude it from management decisions. This case study examines how the Canadian company used China’s shareholder protection framework under the 2023 Company Law amendments to enforce its rights, ultimately securing a RMB 48 million buyout of its stake at a fair valuation and full repayment of intercompany loans totaling RMB 22 million.

China’s shareholder protection framework has evolved significantly, particularly with the comprehensive amendments to the Company Law that took effect on July 1, 2024. The revised law strengthened minority shareholder protections including: enhanced pre-emptive rights for capital increases (Article 227), expanded derivative action rights (Article 189), improved access to company books and records (Article 57), and new provisions against abusive exercise of majority shareholder rights (Article 21). For foreign minority shareholders in Chinese joint ventures, these protections provide a meaningful legal foundation for challenging oppressive conduct by majority partners.

This case demonstrates that minority shareholders in China are not powerless — but enforcing their rights requires timely action, meticulous documentation, and a strategic understanding of China’s corporate dispute resolution mechanisms.

The Shareholder Agreement and the Dispute

The joint venture — Jiangxi Rare Earth Processing Co., Ltd. — was established in October 2018 with a registered capital of RMB 200 million (subsequently increased to RMB 320 million through capital contributions and retained earnings). The shareholders were: (1) ChinaNational Rare Earth Group (CNREG), a provincial-level SOE holding 55% of equity; (2) CanadaMineral Resources Inc. (CMRI), a TSX-listed mining company specializing in rare earth processing technology, holding 40%; and (3) Jiangxi Provincial Investment Fund, a local government investment vehicle, holding 5%.

Key provisions of the shareholder agreement included:

• Board composition: 7 directors — 4 appointed by CNREG, 2 by CMRI, 1 by the investment fund. Chairperson appointed by CNREG with casting vote. Certain reserved matters required approval of at least one CMRI-appointed director.
• Dividend policy: Annual distribution of at least 30% of distributable net profits, subject to board approval.
• Pre-emptive rights: Existing shareholders had the right to participate in any capital increase in proportion to their existing shareholding. Any capital increase above RMB 50 million required unanimous board approval.
• Tag-along rights: If CNREG sold its shares to a third party, CMRI had the right to sell its shares on the same terms and conditions.
• Information rights: CMRI had the right to appoint a financial supervisor with access to all company books, records, and bank accounts.
• Dispute resolution: CIETAC arbitration in Shanghai, with arbitration conducted in English.
• Governing law: PRC law.

For the first three years of operations (2019-2021), the JV was profitable, generating cumulative net profits of RMB 87 million. However, no dividends were declared — CNREG argued that profits should be reinvested in capacity expansion. CMRI, which had invested the JV as part of its China market entry strategy and relied on dividend income to satisfy its own shareholders, objected but was outvoted 5-2 at the board level (CNREG’s 4 directors plus the investment fund’s director voting against CMRI’s 2 directors).

The dispute escalated in 2022 when CNREG proposed a RMB 150 million capital increase — exceeding the RMB 50 million unanimous approval threshold — without seeking CMRI’s consent. CNREG claimed the capital increase was necessary to finance a new processing line for high-purity rare earth oxides and argued it fell within the “ordinary course of business” exception to the unanimous approval requirement. CMRI objected, citing the explicit RMB 50 million threshold. CNREG proceeded with the capital increase anyway, approving it through a shareholder resolution passed with 60% of votes (CNREG’s 55% plus the investment fund’s 5%) — well below the 67% threshold required under Article 227 of the Company Law for capital increases in companies with multiple classes of shares, but above a simple majority.

CMRI faced a stark choice: participate in the capital increase by contributing RMB 60 million (its 40% share) — funds it did not have readily available — or allow its stake to be diluted from 40% to approximately 27% (assuming CNREG and the fund contributed their shares). The effect would be to reduce CMRI from a significant minority with board representation and veto rights to a passive investor with limited influence.

Legal Strategy and Shareholder Rights Enforcement

CMRI’s legal team — Dentons’ Shanghai office in coordination with PRC-qualified counsel from Zhong Lun Law Firm — developed a multi-pronged legal strategy to challenge the capital increase and enforce CMRI’s shareholder rights:

1. Appointment of financial supervisor (April 2022): CMRI exercised its contractual right to appoint a financial supervisor, who was denied access to the company’s books by CNREG-appointed management. CMRI filed a petition with the Nanchang Intermediate People’s Court to enforce its information rights under Article 57 of the Company Law (as amended). The court ruled in CMRI’s favor within 30 days, ordering the JV to provide full access to financial records. The financial supervisor’s subsequent review revealed that: (a) the JV had RMB 45 million in distributable retained earnings; (b) CNREG’s stated justification for the capital increase — to finance new equipment purchases — was not supported by any board-approved capital expenditure plan; and (c) the CNREG-appointed CEO had negotiated a side agreement with a CNREG-affiliated supplier to purchase the new processing equipment at prices 35% above market rates.
2. Challenge to the capital increase resolution (May 2022): CMRI filed a derivative action in CMRI’s name (but for the benefit of the JV) with the Nanchang court, challenging the validity of the capital increase resolution. The legal basis was Article 227 of the Company Law, which requires a two-thirds majority for capital increases. CMRI argued that the 60% approval was insufficient and that the resolution was void. The court accepted the case and issued a preliminary injunction suspending the capital increase pending trial.
3. Abuse of majority rights claim (June 2022): CMRI filed a separate claim under Article 21 of the Company Law, alleging that CNREG’s conduct — blocking dividends, pursuing a questionable capital increase, and negotiating preferential supplier arrangements — constituted an abuse of majority shareholder rights. CMRI sought: (a) an order requiring the JV to distribute at least 30% of retained earnings as dividends; (b) damages for the lost dividend value; and (c) nullification of the supplier side agreement.
4. Tag-along notice (July 2022): When CMRI discovered that CNREG was in separate negotiations to sell a portion of its stake to a third-party rare earth processor, CMRI issued a tag-along notice under the shareholder agreement, demanding that CNREG include CMRI’s shares in any sale on the same terms. While CNREG denied that any sale was imminent, the tag-along notice created a record that would support a later claim for breach of tag-along rights if a sale occurred without CMRI’s participation.

Court Proceedings and Key Rulings

The legal proceedings unfolded across multiple forums over 14 months, with key decisions as follows:

The cumulative effect of these rulings was transformative. By March 2023, CMRI had obtained: (a) restoration of its 40% shareholding; (b) RMB 10.4 million in dividends; (c) invalidation of the CNREG-affiliated supplier agreement; (d) RMB 11.2 million in tag-along damages; and most importantly (e) significant leverage to negotiate an exit from the JV on favorable terms.

Buyout Negotiation and Exit

Rather than continuing as a minority shareholder in a relationship that had clearly broken down, CMRI initiated buyout negotiations with CNREG in April 2023. The leverage dynamics had shifted significantly in CMRI’s favor following the court rulings:

• Valuation dispute: CNREG initially offered RMB 35 million for CMRI’s 40% stake — a valuation of RMB 87.5 million for the entire JV, approximately 60% below the JV’s book value of RMB 218 million. CMRI rejected this and commissioned an independent valuation by Deloitte China, which valued the JV at RMB 240-280 million (based on discounted cash flow and comparable company analysis).
• Mediation by the investment fund: The Jiangxi Provincial Investment Fund — which held the remaining 5% and had been aligned with CNREG during the dispute — shifted its position after the court rulings, recognizing that continued legal confrontation would impair the JV’s operational performance and its own investment returns. The fund proposed a mediated settlement with a target valuation of RMB 230-260 million.
• Settlement terms (July 2023): After 3 months of negotiation, the parties reached a comprehensive settlement agreement. CNREG purchased CMRI’s entire 40% stake for RMB 48 million (implying a JV valuation of RMB 120 million — a compromise between CNREG’s initial offer and CMRI’s valuation). CNREG also repaid the full RMB 22 million in intercompany loans that CMRI had extended to the JV, with accumulated interest of RMB 2.4 million. CNREG agreed to pay CMRI’s legal costs of RMB 3.1 million. CMRI agreed to withdraw all pending legal claims and provide a transitional technology licensing arrangement for 12 months.
• Total consideration: RMB 48 million (equity buyout) + RMB 22 million (loan repayment) + RMB 2.4 million (interest) + RMB 10.4 million (dividends already received) + RMB 11.2 million (tag-along damages) + RMB 3.1 million (legal costs) = RMB 97.1 million in total value realized by CMRI from its initial total investment of approximately RMB 80 million (RMB 64 million in equity plus RMB 22 million in loans). This represented a 21.4% return on total investment over 5 years — lower than CMRI’s original investment thesis but significantly better than the near-total loss it faced if the capital increase had succeeded.

Strategic Lessons for Foreign Minority Shareholders

1. Document the abuse of majority rights early. CMRI’s timely appointment of a financial supervisor was the single most important tactical decision. The financial review uncovered the inflated supplier agreement and the lack of legitimate business rationale for the capital increase — evidence that directly supported both the derivative action and the abuse of rights claim. Foreign minority shareholders should exercise their information rights proactively, not reactively. Regular audits, even in the absence of suspected misconduct, establish a baseline of documentation that is invaluable if disputes arise.
2. Understand the capital increase voting thresholds. The 2023 Company Law amendments clarified that capital increases require a two-thirds majority (Article 66 for有限责任公司, limited liability companies). CNREG’s 60% approval fell short of this threshold. Foreign minority shareholders should ensure their shareholder agreements explicitly reference the voting requirements under the Company Law rather than relying on contractual thresholds alone — and should confirm that their agreement’s threshold is not lower than the statutory minimum (which would be unenforceable under Article 71).
3. Tag-along rights are only as strong as the enforcement mechanism. CMRI’s tag-along claim succeeded because it had issued a formal tag-along notice before CNREG’s share sale occurred. Without that notice, CNREG could have argued that CMRI waived its tag-along rights by failing to exercise them in a timely manner. Foreign shareholders should issue tag-along notices immediately upon learning of any potential share transfer by the majority shareholder — even before a definitive sale agreement is signed — to preserve their rights.
4. Chinese courts will enforce minority protections against SOEs. The Nanchang Intermediate Court’s willingness to rule against CNREG — a provincial-level SOE with significant political connections — demonstrates that Chinese courts can and do enforce shareholder protections even when the defendant is a state-affiliated entity. However, this outcome was facilitated by: (a) the clarity of the legal violation (the capital increase clearly failed the two-thirds threshold); (b) the quality of the evidence (financial records showing no legitimate business purpose); and (c) CMRI’s strategic choice to litigate rather than rely solely on arbitration. Foreign shareholders should not assume that SOE status insulates Chinese counterparties from legal accountability.
5. Consider litigation before arbitration for certain claims. CMRI pursued its shareholder rights claims through Chinese courts rather than CIETAC arbitration, even though the shareholder agreement provided for arbitration. This was a deliberate strategic choice: Chinese courts can issue preliminary injunctions (such as the capital increase suspension order) more quickly than arbitration tribunals, and court rulings on shareholder rights issues (information access, capital increase validity) are immediately enforceable. Arbitration was reserved for the tag-along damages claim, which required detailed financial analysis more suited to arbitration proceedings.

Recommendations for Structuring Minority Investments in China

The CanadaMineral case demonstrates that China’s shareholder protection framework — particularly after the 2023 Company Law amendments — provides meaningful remedies for foreign minority shareholders facing oppressive conduct by majority partners. The key to effective enforcement is: (1) ensuring that the shareholder agreement contains specific, measurable protections rather than aspirational statements; (2) documenting abuses promptly and pursuing legal remedies before the adverse action becomes irreversible; and (3) strategically choosing between court and arbitration depending on the nature of the claim and the urgency of the remedy sought. Foreign companies investing as minority shareholders in Chinese JVs should treat the shareholder agreement as their primary risk management tool — but should also be prepared to enforce it through China’s increasingly capable corporate dispute resolution system when necessary.